The dual role of cellular senescence in human tumor progression and therapy

Abstract

Cellular senescence, one of the hallmarks of cancer, is characterized by cell cycle arrest and the loss of most normal cellular functions while acquiring a hypersecretory, proinflammatory phenotype. The function of senescent cells in cancer cells varies depending on the cellular conditions. Before the occurrence of cancer, senescent cells act as a barrier to prevent its development. But once cancer has occurred, senescent cells play a procancer role. However, few of the current studies have adequately explained the diversity of cellular senescence across cancers. Herein, we concluded the latest intrinsic mechanisms of cellular senescence in detail and emphasized the senescence-associated secretory phenotype as a key contributor to heterogeneity of senescent cells in tumor. We also discussed five kinds of inducers of cellular senescence and the advancement of senolytics in cancer, which are drugs that tend to clear senescent cells. Finally, we summarized the various effects of senescent cells in different cancers and manifested that their functions may be diametrically opposed under different circumstances. In short, this paper contributes to the understanding of the diversity of cellular senescence in cancers and provides novel insight for tumor therapy.

Keywords

cellular senescence / cGAS–STING / SASP / senolytic / therapy-induced senescence

References

[1] Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961; 25: 585-621.

[2] d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003; 426(6963): 194-198.

[3] Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990; 345(6274): 458-460.

[4] Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997; 88(5): 593-602.

[5] Coppé JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008; 6(12): 2853-2868.

[6] Kuilman T, Michaloglou C, Vredeveld LC, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008; 133(6): 1019-1031.

[7] Acosta JC, O’Loghlen A, Banito A, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell. 2008; 133(6): 1006-1018.

[8] Baker DJ, Perez-Terzic C, Jin F, et al. Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. Nat Cell Biol. 2008; 10(7): 825-836.

[9] Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011; 479(7372): 232-236.

[10] Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015; 14(4): 644-658.

[11] Demaria M, O’Leary MN, Chang J, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 2017; 7(2): 165-176.

[12] Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022; 12(1): 31-46.

[13] Li Y, Zhao H, Huang X, et al. Embryonic senescent cells re-enter cell cycle and contribute to tissues after birth. Cell Res. 2018; 28(7): 775-778.

[14] Calcinotto A, Kohli J, Zagato E, Pellegrini L, Demaria M, Alimonti A. Cellular senescence: aging, cancer, and injury. Physiol Rev. 2019; 99(2): 1047-1078.

[15] Song B, Yang P, Zhang S. Cell fate regulation governed by p53: friends or reversible foes in cancer therapy. Cancer Commun (Lond). 2024; 44(3): 297-360.

[16] Pezone A, Olivieri F, Napoli MV, Procopio A, Avvedimento EV, Gabrielli A. Inflammation and DNA damage: cause, effect or both. Nat Rev Rheumatol. 2023; 19(4): 200-211.

[17] Yousefzadeh M, Henpita C, Vyas R, Soto-Palma C, Robbins P, Niedernhofer L. DNA damage-how and why we age? eLife. 2021; 10: e62852.

[18] Wang M, Brandt LTL, Wang X, et al. Genotoxic aldehyde stress prematurely ages hematopoietic stem cells in a p53-driven manner. Mol Cell. 2023; 83(14): 2417-2433. e2417.

[19] Aubert G, Lansdorp PM. Telomeres and aging. Physiol Rev. 2008; 88(2): 557-579.

[20] Guo Z, Wang G, Wu B, et al. DCAF1 regulates Treg senescence via the ROS axis during immunological aging. J Clin Invest. 2020; 130(11): 5893-5908.

[21] Liu C, Rokavec M, Huang Z, Hermeking H. Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis. Cell Death Differ. 2023; 30(7): 1771-1785.

[22] Feinberg AP, Levchenko A. Epigenetics as a mediator of plasticity in cancer. Science. 2023; 379(6632): eaaw3835.

[23] Wiley CD, Velarde MC, Lecot P, et al. Mitochondrial dysfunction induces senescence with a distinct secretory phenotype. Cell Metab. 2016; 23(2): 303-314.

[24] Xie H, Zhou L, Liu F, et al. Autophagy induction regulates aquaporin 3-mediated skin fibroblast ageing. Br J Dermatol. 2022; 186(2): 318-333.

[25] Weyemi U, Lagente-Chevallier O, Boufraqech M, et al. ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene. 2012; 31(9): 1117-1129.

[26] Yang JH, Hayano M, Griffin PT, et al. Loss of epigenetic information as a cause of mammalian aging. Cell. 2023; 186(2): 305-326. e327.

[27] Acevedo M, Vernier M, Mignacca L, et al. A CDK4/6-dependent epigenetic mechanism protects cancer cells from PML-induced senescence. Cancer Res. 2016; 76(11): 3252-3264.

[28] Kohli J, Ge C, Fitsiou E, et al. Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression. Nat Commun. 2022; 13(1): 7923.

[29] Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018; 36: 18-28.

[30] Schneider NFZ, Persich L, Rocha SC, et al. Cytotoxic and cytostatic effects of digitoxigenin monodigitoxoside (DGX) in human lung cancer cells and its link to Na, K-ATPase. Biomed Pharmacother. 2018; 97: 684-696.

[31] Hubackova S, Kucerova A, Michlits G, et al. IFNγ induces oxidative stress, DNA damage and tumor cell senescence via TGFβ/SMAD signaling-dependent induction of Nox4 and suppression of ANT2. Oncogene. 2016; 35(10): 1236-1249.

[32] Sun X, Thorne RF, Zhang XD, et al. LncRNA GUARDIN suppresses cellular senescence through a LRP130-PGC1α-FOXO4-p21-dependent signaling axis. EMBO Rep. 2020; 21(4): e48796.

[33] Fuhrmann-Stroissnigg H, Ling YY, Zhao J, et al. Identification of HSP90 inhibitors as a novel class of senolytics. Nat Commun. 2017; 8(1): 422.

[34] Colom Díaz PA, Mistry JJ, Trowbridge JJ. Hematopoietic stem cell aging and leukemia transformation. Blood. 2023; 142(6): 533-542.

[35] Tubita A, Lombardi Z, Tusa I, et al. Inhibition of ERK5 elicits cellular senescence in melanoma via the cyclin-dependent kinase inhibitor p21. Cancer Res. 2022; 82(3): 447-457.

[36] Helman A, Klochendler A, Azazmeh N, et al. p16(Ink4a)-induced senescence of pancreatic beta cells enhances insulin secretion. Nat Med. 2016; 22(4): 412-420.

[37] de Paula B, Kieran R, Koh SSY, Crocamo S, Abdelhay E, Muñoz-Espín D. Targeting senescence as a therapeutic opportunity for triple-negative breast cancer. Mol Cancer Ther. 2023; 22(5): 583-598.

[38] Fiard G, Stavrinides V, Chambers ES, et al. Cellular senescence as a possible link between prostate diseases of the ageing male. Nat Rev Urol. 2021; 18(10): 597-610.

[39] Jha SK, De Rubis G, Devkota SR, et al. Cellular senescence in lung cancer: molecular mechanisms and therapeutic interventions. Ageing Res Rev. 2024; 97: 102315.

[40] Neurohr GE, Terry RL, Lengefeld J, et al. Excessive cell growth causes cytoplasm dilution and contributes to senescence. Cell. 2019; 176(5): 1083-1097. e1018.

[41] Freund A, Patil CK, Campisi J. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J. 2011; 30(8): 1536-1548.

[42] Liu F, Wu S, Ren H, Gu J. Klotho suppresses RIG-I-mediated senescence-associated inflammation. Nat Cell Biol. 2011; 13(3): 254-262.

[43] Laberge RM, Sun Y, Orjalo AV, et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol. 2015; 17(8): 1049-1061.

[44] Strzeszewska A, Alster O, Mosieniak G, Ciolko A, Sikora E. Insight into the role of PIKK family members and NF-кB in DNAdamage-induced senescence and senescence-associated secretory phenotype of colon cancer cells. Cell Death Dis. 2018; 9(2): 44.

[45] Chien Y, Scuoppo C, Wang X, et al. Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev. 2011; 25(20): 2125-2136.

[46] Glück S, Guey B, Gulen MF, et al. Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. Nat Cell Biol. 2017; 19(9): 1061-1070.

[47] Omer A, Barrera MC, Moran JL, et al. G3BP1 controls the senescence-associated secretome and its impact on cancer progression. Nat Commun. 2020; 11(1): 4979.

[48] Yang H, Wang H, Ren J, Chen Q, Chen ZJ. cGAS is essential for cellular senescence. Proc Natl Acad Sci USA. 2017; 114(23): E4612-E4620.

[49] Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature. 2017; 548(7668): 466-470.

[50] Hopfner K-P, Hornung V. Molecular mechanisms and cellular functions of cGAS–STING signalling. Nat Rev Mol Cell Biol. 2020; 21(9): 501-521.

[51] Takahashi A, Loo TM, Okada R, et al. Downregulation of cytoplasmic DNases is implicated in cytoplasmic DNA accumulation and SASP in senescent cells. Nat Commun. 2018; 9(1): 1249.

[52] De Cecco M, Ito T, Petrashen AP, et al. L1 drives IFN in senescent cells and promotes age-associated inflammation. Nature. 2019; 566(7742): 73-78.

[53] Liang C, Ke Q, Liu Z, et al. BMAL1 moonlighting as a gatekeeper for LINE1 repression and cellular senescence in primates. Nucleic Acids Res. 2022; 50(6): 3323-3347.

[54] Benitez-Guijarro M, Lopez-Ruiz C, Tarnauskaitė Ž, et al. RNase H2, mutated in Aicardi-Goutières syndrome, promotes LINE-1 retrotransposition. EMBO J. 2018; 37(15): e98506.

[55] Hubackova S, Krejcikova K, Bartek J, Hodny Z. IL1-and TGFβ-Nox4 signaling, oxidative stress and DNA damage response are shared features of replicative, oncogene-induced, and drug-induced paracrine ‘bystander senescence’. Aging (Albany NY). 2012; 4(12): 932-951.

[56] Demaria M, Ohtani N, Youssef SA, et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell. 2014; 31(6): 722-733.

[57] Storer M, Mas A, Robert-Moreno A, et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell. 2013; 155(5): 1119-1130.

[58] Muñoz-Espín D, Cañamero M, Maraver A, et al. Programmed cell senescence during mammalian embryonic development. Cell. 2013; 155(5): 1104-1118.

[59] Ruhland MK, Loza AJ, Capietto A-H, et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat Commun. 2016; 7(1): 11762.

[60] Eggert T, Wolter K, Ji J, et al. Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression. Cancer Cell. 2016; 30(4): 533-547.

[61] Burton DG, Krizhanovsky V. Physiological and pathological consequences of cellular senescence. Cell Mol Life Sci. 2014; 71(22): 4373-4386.

[62] Hernandez-Segura A, de Jong TV, Melov S, Guryev V, Campisi J, Demaria M. Unmasking transcriptional heterogeneity in senescent cells. Curr Biol. 2017; 27(17): 2652-2660. e2654.

[63] Hall BM, Balan V, Gleiberman AS, et al. p16(Ink4a) and senescence-associated β-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli. Aging. 2017; 9(8): 1867-1884.

[64] Baar MP, Brandt RMC, Putavet DA, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017; 169(1): 132-147. e116.

[65] Latorre E, Torregrossa R, Wood ME, Whiteman M, Harries LW. HNRNPDMitochondria-targeted hydrogen sulfide attenuates endothelial senescence by selective induction of splicing factors and. Aging (Albany NY). 2018; 10(7): 1666-1681.

[66] Hine C, Harputlugil E, Zhang Y, et al. Endogenous hydrogen sulfide production is essential for dietary restriction benefits. Cell. 2015; 160(1-2): 132-144.

[67] Rowland BD, Bernards R, Peeper DS. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol. 2005; 7(11): 1074-1082.

[68] Gil J. The challenge of identifying senescent cells. Nat Cell Biol. 2023; 25(11): 1554-1556.

[69] Wang B, Kohli J, Demaria M. Senescent cells in cancer therapy: friends or foes? Trends Cancer. 2020; 6(10): 838-857.

[70] Pan C, Zhou F, Zhang L. The loss of epigenetic information: not only consequences but a cause of mammalian aging. Signal Transduct Target Ther. 2023; 8(1): 140.

[71] Beauséjour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 2003; 22(16): 4212-4222.

[72] Rodier F, Campisi J, Bhaumik D. Two faces of p53: aging and tumor suppression. Nucleic Acids Res. 2007; 35(22): 7475-7484.

[73] Fletcher-Sananikone E, Kanji S, Tomimatsu N, et al. Elimination of radiation-induced senescence in the brain tumor microenvironment attenuates glioblastoma recurrence. Cancer Res. 2021; 81(23): 5935-5947.

[74] Fumagalli M, Rossiello F, Clerici M, et al. Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation. Nat Cell Biol. 2012; 14(4): 355-365.

[75] Rodier F, Coppé JP, Patil CK, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009; 11(8): 973-979.

[76] Mojiri A, Walther BK, Jiang C, et al. Telomerase therapy reverses vascular senescence and extends lifespan in progeria mice. Eur Heart J. 2021; 42(42): 4352-4369.

[77] Ramirez RD, Morales CP, Herbert BS, et al. Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Genes Dev. 2001; 15(4): 398-403.

[78] Yang R, Han Y, Guan X, et al. Regulation and clinical potential of telomerase reverse transcriptase (TERT/hTERT) in breast cancer. Cell Commun Signal. 2023; 21(1): 218.

[79] Leão R, Apolónio JD, Lee D, Figueiredo A, Tabori U, Castelo-Branco P. Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. J Biomed Sci. 2018; 25(1): 22.

[80] Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 1997; 91(1): 25-34.

[81] Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci USA. 1994; 91(21): 9857-9860.

[82] Shahin WS, Ebed SO, Tyler SR, et al. Redox-dependent Igfbp2 signaling controls Brca1 DNA damage response to govern neural stem cell fate. Nat Commun. 2023; 14(1): 444.

[83] Gordon CA, Madamanchi NR, Runge MS, Jarstfer MB. Effect of oxidative stress on telomere maintenance in aortic smooth muscle cells. Biochim Biophys Acta Mol Basis Dis. 2022; 1868(7): 166397.

[84] Griñán-Ferré C, Bellver-Sanchis A, Izquierdo V, et al. The pleiotropic neuroprotective effects of resveratrol in cognitive decline and Alzheimer’s disease pathology: from antioxidant to epigenetic therapy. Ageing Res Rev. 2021; 67: 101271.

[85] Ngoi NY, Liew AQ, Chong SJF, Davids MS, Clement MV, Pervaiz S. The redox-senescence axis and its therapeutic targeting. Redox Biol. 2021; 45: 102032.

[86] Zhang H, Davies KJA, Forman HJ. Oxidative stress response and Nrf2 signaling in aging. Free Radic Biol Med. 2015; 88: 314-336.

[87] Luo M, Bao L, Xue Y, et al. ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2. J Clin Invest. 2024; 134(6): e171166.

[88] Wang X, Zhou T, Yang X, et al. DDRGK1 enhances osteosarcoma chemoresistance via inhibiting KEAP1-mediated NRF2 ubiquitination. Adv Sci (Weinh). 2023; 10(14): e2204438.

[89] Kubben N, Zhang W, Wang L, et al. Repression of the antioxidant NRF2 pathway in premature aging. Cell. 2016; 165(6): 1361-1374.

[90] Ungvari Z, Tarantini S, Nyúl-Tóth Á, et al. Nrf2 dysfunction and impaired cellular resilience to oxidative stressors in the aged vasculature: from increased cellular senescence to the pathogenesis of age-related vascular diseases. Geroscience. 2019; 41(6): 727-738.

[91] Chen H, Han Z, Luo Q, et al. Radiotherapy modulates tumor cell fate decisions: a review. Radiat Oncol. 2022; 17(1): 196.

[92] Benítez S, Cordero A, Santamaría PG, et al. RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness. Dev Cell. 2021; 56(12): 1727-1741. e1727.

[93] Prasanna PG, Citrin DE, Hildesheim J, et al. Therapy-induced senescence: opportunities to improve anticancer therapy. J Natl Cancer Inst. 2021; 113(10): 1285-1298.

[94] Efimova EV, Mauceri HJ, Golden DW, et al. Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res. 2010; 70(15): 6277-6282.

[95] Koch CM, Reck K, Shao K, et al. Pluripotent stem cells escape from senescence-associated DNA methylation changes. Genome Res. 2013; 23(2): 248-259.

[96] Franzen J, Wagner W, Fernandez-Rebollo E. Epigenetic modifications upon senescence of mesenchymal stem cells. Curr Stem Cell Rep. 2016; 2(3): 248-254.

[97] Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349(21): 2042-2054.

[98] Chakrabarty A, Chakraborty S, Bhattacharya R, Chowdhury G. Senescence-induced chemoresistance in triple negative breast cancer and evolution-based treatment strategies. Front Oncol. 2021; 11: 674354-674354.

[99] McDermott MSJ, Conlon N, Browne BC, et al. HER2-targeted tyrosine kinase inhibitors cause therapy-induced-senescence in breast cancer cells. Cancers (Basel). 2019; 11(2): 197.

[100] Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res. 2003; 63(11): 2705-2715.

[101] Nacarelli T, Azar A, Sell C. Mitochondrial stress induces cellular senescence in an mTORC1-dependent manner. Free Radic Biol Med. 2016; 95: 133-154.

[102] Dikovskaya D, Cole John J, Mason Susan M, et al. Mitotic stress is an integral part of the oncogene-induced senescence program that promotes multinucleation and cell cycle arrest. Cell Rep. 2015; 12(9): 1483-1496.

[103] Scialò F, Sriram A, Fernández-Ayala D, et al. Mitochondrial ROS produced via reverse electron transport extend animal lifespan. Cell Metab. 2016; 23(4): 725-734.

[104] Balliet RM, Capparelli C, Guido C, et al. Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: understanding the aging and cancer connection. Cell Cycle. 2011; 10(23): 4065-4073.

[105] Tharp KM, Higuchi-Sanabria R, Timblin GA, et al. Adhesion-mediated mechanosignaling forces mitohormesis. Cell Metab. 2021; 33(7): 1322-1341. e1313.

[106] Guarente L, Sinclair DA, Kroemer G. Human trials exploring anti-aging medicines. Cell Metab. 2024; 36(2): 354-376.

[107] Dou X, Fu Q, Long Q, et al. PDK4-dependent hypercatabolism and lactate production of senescent cells promotes cancer malignancy. Nat Metab. 2023; 5(11): 1887-1910.

[108] Espada L, Dakhovnik A, Chaudhari P, et al. Loss of metabolic plasticity underlies metformin toxicity in aged Caenorhabditis elegans. Nat Metab. 2020; 2(11): 1316-1331.

[109] Le Pelletier L, Mantecon M, Gorwood J, et al. Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. eLife. 2021; 10: e62635.

[110] Sekar P, Hsiao G, Hsu SH, Huang DY, Lin WW, Chan CM. Metformin inhibits methylglyoxal-induced retinal pigment epithelial cell death and retinopathy via AMPK-dependent mechanisms: reversing mitochondrial dysfunction and upregulating glyoxalase 1. Redox Biol. 2023; 64: 102786.

[111] Ridwan SM, Emlein R, Mesbahi A, Annabi A, Hainfeld JF, Smilowitz HM. Radiation-induced dormancy of intracerebral melanoma: endotoxin inflammation leads to both shortened tumor dormancy and long-term survival with localized senescence. Cancer Immunol Immunother. 2023; 72(11): 3851-3859.

[112] Wu Z, Uhl B, Gires O, Reichel CA. A transcriptomic pan-cancer signature for survival prognostication and prediction of immunotherapy response based on endothelial senescence. J Biomed Sci. 2023; 30(1): 21.

[113] Hwang HJ, Lee YR, Kang D, et al. Endothelial cells under therapy-induced senescence secrete CXCL11, which increases aggressiveness of breast cancer cells. Cancer Lett. 2020; 490: 100-110.

[114] Liu X, Hartman CL, Li L, et al. Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy. Sci Transl Med. 2021; 13(587): eaaz6314.

[115] Liu X, Si F, Bagley D, et al. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy. J Immunother Cancer. 2022; 10(10): e005020.

[116] Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. 2016; 15(3): 428-435.

[117] Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020; 288(5): 518-536.

[118] Guerrero A, Herranz N, Sun B, et al. Cardiac glycosides are broad-spectrum senolytics. Nat Metab. 2019; 1(11): 1074-1088.

[119] Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008; 68(9): 3421-3428.

[120] Mohamad Anuar NN, Nor Hisam NS, Liew SL, Ugusman A. Clinical review: navitoclax as a pro-apoptotic and anti-fibrotic agent. Front Pharmacol. 2020; 11: 564108-564108.

[121] Zhu Y, Doornebal EJ, Pirtskhalava T, et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-X(L) inhibitors, A1331852 and A1155463. Aging. 2017; 9(3): 955-963.

[122] Jia Y, Han L, Ramage CL, et al. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica. 2023; 108(10): 2626-2638.

[123] Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018; 24(8): 1246-1256.

[124] Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019; 40: 554-563.

[125] Syed DN, Adhami VM, Khan MI, Mukhtar H. Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin. Anticancer Agents Med Chem. 2013; 13(7): 995-1001.

[126] Chamcheu JC, Esnault S, Adhami VM, et al. Fisetin, a 3, 7, 3’ 4’-tetrahydroxyflavone inhibits the PI3K/Akt/mTOR and MAPK pathways and ameliorates psoriasis pathology in 2D and 3D organotypic human inflammatory skin models. Cells. 2019; 8(9): 1089.

[127] Mirzaei H, Shakeri A, Rashidi B, Jalili A, Banikazemi Z, Sahebkar A. Phytosomal curcumin: a review of pharmacokinetic, experimental and clinical studies. Biomed Pharmacother. 2017; 85: 102-112.

[128] Yallapu MM, Nagesh PK, Jaggi M, Chauhan SC. Therapeutic applications of curcumin nanoformulations. AAPS J. 2015; 17(6): 1341-1356.

[129] Triana-Martínez F, Picallos-Rabina P, Da Silva-Álvarez S, et al. Identification and characterization of cardiac glycosides as senolytic compounds. Nat Commun. 2019; 10(1): 4731.

[130] Martin N, Soriani O, Bernard D. Cardiac glycosides as senolytic compounds. Trends Mol Med. 2020; 26(3): 243-245.

[131] Woo SH, Mo YJ, Lee YI, et al. ANT2 accelerates cutaneous wound healing in aged skin by regulating energy homeostasis and inflammation. J Invest Dermatol. 2023; 143(11): 2295-2310. e2217.

[132] Hubackova S, Davidova E, Rohlenova K, et al. Selective elimination of senescent cells by mitochondrial targeting is regulated by ANT2. Cell Death Differ. 2019; 26(2): 276-290.

[133] He Q, Xue S, Tan Y, et al. Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer. Cancer Lett. 2019; 448: 94-104.

[134] Liao EC, Hsu YT, Chuah QY, et al. Radiation induces senescence and a bystander effect through metabolic alterations. Cell Death Dis. 2014; 5(5): e1255.

[135] Holz O, Zühlke I, Jaksztat E, et al. Lung fibroblasts from patients with emphysema show a reduced proliferation rate in culture. Eur Respir J. 2004; 24(4): 575-579.

[136] Bourgeois B, Madl T. Regulation of cellular senescence via the FOXO4-p53 axis. FEBS Lett. 2018; 592(12): 2083-2097.

[137] Amor C, Feucht J, Leibold J, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020; 583(7814): 127-132.

[138] Walters HE, Deneka-Hannemann S, Cox LS. Reversal of phenotypes of cellular senescence by pan-mTOR inhibition. Aging. 2016; 8(2): 231-244.

[139] Blättler SM, Cunningham JT, Verdeguer F, et al. Yin Yang 1 deficiency in skeletal muscle protects against rapamycin-induced diabetic-like symptoms through activation of insulin/IGF signaling. Cell Metab. 2012; 15(4): 505-517.

[140] Trelinska J, Dachowska I, Kotulska K, Fendler W, Jozwiak S, Mlynarski W. Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening. Anticancer Drugs. 2015; 26(4): 437-442.

[141] Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 2011; 10(11): 868-880.

[142] Mahoney SJ, Narayan S, Molz L, et al. A small molecule inhibitor of Rheb selectively targets mTORC1 signaling. Nat Commun. 2018; 9(1): 548.

[143] Schreiber KH, Arriola Apelo SI, Yu D, et al. A novel rapamycin analog is highly selective for mTORC1 in vivo. Nat Commun. 2019; 10(1): 3194.

[144] Wang C, Vegna S, Jin H, et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature. 2019; 574(7777): 268-272.

[145] Wang W, Zheng Y, Sun S, et al. A genome-wide CRISPR-based screen identifies KAT7 as a driver of cellular senescence. Sci Transl Med. 2021; 13(575): eabd2655.

[146] MacPherson L, Anokye J, Yeung MM, et al. HBO1 is required for the maintenance of leukaemia stem cells. Nature. 2020; 577(7789): 266-270.

[147] Victorelli S, Salmonowicz H, Chapman J, et al. Apoptotic stress causes mtDNA release during senescence and drives the SASP. Nature. 2023; 622(7983): 627-636.

[148] Vazquez-Villasenor I, Garwood CJ, Simpson JE, Heath PR, Mortiboys H, Wharton SB. Persistent DNA damage alters the neuronal transcriptome suggesting cell cycle dysregulation and altered mitochondrial function. Eur J Neurosci. 2021; 54(9): 6987-7005.

[149] Victorelli S, Lagnado A, Halim J, et al. Senescent human melanocytes drive skin ageing via paracrine telomere dysfunction. EMBO J. 2019; 38(23): e101982.

[150] Faheem MM, Seligson ND, Ahmad SM, et al. Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives. Cell Death Discov. 2020; 6: 51.

[151] Le ON, Rodier F, Fontaine F, et al. Ionizing radiation-induced long-term expression of senescence markers in mice is independent of p53 and immune status. Aging Cell. 2010; 9(3): 398-409.

[152] Carrière C, Gore AJ, Norris AM, et al. Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions. Gastroenterology. 2011; 141(3): 1091-1101.

[153] Liu J, Huang X, Liu D, et al. Demethyleneberberine induces cell cycle arrest and cellular senescence of NSCLC cells via c-Myc/HIF-1α pathway. Phytomedicine. 2021; 91: 153678.

[154] Zhuang D, Mannava S, Grachtchouk V, et al. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene. 2008; 27(52): 6623-6634.

[155] Delestré L, Cui H, Esposito M, et al. Senescence is a Spi1-induced anti-proliferative mechanism in primary hematopoietic cells. Haematologica. 2017; 102(11): 1850-1860.

[156] Xie X, Koh JY, Price S, White E, Mehnert JM. Atg7 overcomes senescence and promotes growth of BrafV600E-driven melanoma. Cancer Discov. 2015; 5(4): 410-423.

[157] Tabor V, Bocci M, Alikhani N, Kuiper R, Larsson LG. MYC synergizes with activated BRAFV600E in mouse lung tumor development by suppressing senescence. Cancer Res. 2014; 74(16): 4222-4229.

[158] Young AP. Senescence triggered by the loss of the VHL tumor suppressor. Cell Cycle. 2008; 7(12): 1709-1712.

[159] Young AP, Schlisio S, Minamishima YA, et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol. 2008; 10(3): 361-369.

[160] Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005; 436(7051): 725-730.

[161] Ludwig S, Klitzsch A, Baniahmad A. The ING tumor suppressors in cellular senescence and chromatin. Cell Biosci. 2011; 1(1): 25.

[162] Moehrle BM, Geiger H. Aging of hematopoietic stem cells: dNA damage and mutations? Exp Hematol. 2016; 44(10): 895-901.

[163] Hellmich C, Moore JA, Bowles KM, Rushworth SA. Bone marrow senescence and the microenvironment of hematological malignancies. Front Oncol. 2020; 10: 230.

[164] Pang WW, Price EA, Sahoo D, et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci USA. 2011; 108(50): 20012-20017.

[165] He H, Xu P, Zhang X, et al. Aging-induced IL27Ra signaling impairs hematopoietic stem cells. Blood. 2020; 136(2): 183-198.

[166] Mitchell E, Spencer Chapman M, Williams N, et al. Clonal dynamics of haematopoiesis across the human lifespan. Nature. 2022; 606(7913): 343-350.

[167] Gu B, Chu J, Wu D. Chimeric antigen receptor T cell therapies for acute myeloid leukemia. Front Med. 2020; 14(6): 701-710.

[168] Bittencourt MCB, Ciurea SO. Recent advances in allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant. 2020; 26(9): e215-e221.

[169] Milanovic M, Yu Y, Schmitt CA. The senescence-stemness alliance—a cancer-hijacked regeneration principle. Trends Cell Biol. 2018; 28(12): 1049-1061.

[170] Duy C, Li M, Teater M, et al. Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence. Cancer Discov. 2021; 11(6): 1542-1561.

[171] Liebig JK, Kuphal S, Bosserhoff AK. HuRdling senescence: huR breaks BRAF-induced senescence in melanocytes and supports melanoma growth. Cancers (Basel). 2020; 12(5): 1299.

[172] Vredeveld LCW, Possik PA, Smit MA, et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2012; 26(10): 1055-1069.

[173] Damsky W, Micevic G, Meeth K, et al. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell. 2015; 27(1): 41-56.

[174] Gladfelter P, Darwish NHE, Mousa SA. Current status and future direction in the management of malignant melanoma. Melanoma Res. 2017; 27(5): 403-410.

[175] Sun X, Shi B, Zheng H, et al. Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway. Cell Death Dis. 2018; 9(3): 260.

[176] Thompson EL, Hu JJ, Niedernhofer LJ. The role of senescent cells in acquired drug resistance and secondary cancer in BRAFi-treated melanoma. Cancers (Basel). 2021; 13(9): 2241.

[177] Pal HC, Sharma S, Strickland LR, et al. Fisetin inhibits human melanoma cell invasion through promotion of mesenchymal to epithelial transition and by targeting MAPK and NFκB signaling pathways. PLoS One. 2014; 9(1): e86338-e86338.

[178] Caltagirone S, Rossi C, Poggi A, et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer. 2000; 87(4): 595-600.

[179] Harris Z, Donovan MG, Branco GM, Limesand KH, Burd R. Quercetin as an emerging anti-melanoma agent: a four-focus area therapeutic development strategy. Front Nutr. 2016; 3: 48-48.

[180] Thangasamy T, Sittadjody S, Lanza-Jacoby S, Wachsberger PR, Limesand KH, Burd R. Quercetin selectively inhibits bioreduction and enhances apoptosis in melanoma cells that overexpress tyrosinase. Nutr Cancer. 2007; 59(2): 258-268.

[181] Song X, Gao T, Lei Q, Zhang L, Yao Y, Xiong J. Piperlongumine induces apoptosis in human melanoma cells via reactive oxygen species mediated mitochondria disruption. Nutr Cancer. 2018; 70(3): 502-511.

[182] Kirkland JL, Tchkonia T, Zhu Y, Niedernhofer LJ, Robbins PD. The clinical potential of senolytic drugs. J Am Geriatr Soc. 2017; 65(10): 2297-2301.

[183] Das Thakur M, Salangsang F, Landman AS, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013; 494(7436): 251-255.

[184] Palmero I, Pantoja C, Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature. 1998; 395(6698): 125-126.

[185] Radiloff DR, Wakeman TP, Feng J, Schilling S, Seto E, Wang X-F. Trefoil factor 1 acts to suppress senescence induced by oncogene activation during the cellular transformation process. Proceedings of the National Academy of Sciences. 2011; 108(16): 6591-6596.

[186] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394-424.

[187] Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer—clinical challenges and opportunities. Nat Rev Clin Oncol. 2020; 17(9): 527-540.

[188] Özdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014; 25(6): 719-734.

[189] Ruscetti M, Morris JP, Mezzadra R, et al. Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer. Cell. 2020; 181(2): 424-441. e421.

[190] Lv X, Lu X, Cao J, et al. Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Science. 2023; 381(6662): eabn4180.

[191] Park MH, Choi JE, Kim JR, Bae YK. Immunohistochemical expressions of senescence-associated secretory phenotype and its association with immune microenvironments and clinicopathological factors in invasive breast cancer. Pathol Oncol Res. 2021; 27: 1609795.

[192] Pare R, Soon PS, Shah A, Lee CS. Differential expression of senescence tumour markers and its implications on survival outcomes of breast cancer patients. PLoS One. 2019; 14(4): e0214604-e0214604.

[193] Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med. 2006; 174(8): 886-893.

[194] Hosgood HD 3rd, Menashe I, He X, Chanock S, Lan Q. PTEN identified as important risk factor of chronic obstructive pulmonary disease. Respir Med. 2009; 103(12): 1866-1870.

[195] Yanagisawa S, Baker JR, Vuppusetty C, et al. Decreased phosphatase PTEN amplifies PI3K signaling and enhances proinflammatory cytokine release in COPD. Am J Physiol Lung Cell Mol Physiol. 2017; 313(2): L230-L239.

[196] Saleh T, Carpenter VJ, Tyutyunyk-Massey L, et al. Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-X(L) - BAX interaction. Mol Oncol. 2020; 14(10): 2504-2519.

[197] Jiao D, Zheng X, Du X, et al. Immunogenic senescence sensitizes lung cancer to LUNX-targeting therapy. Cancer Immunol Immunother. 2022; 71(6): 1403-1417.

[198] Guccini I, Revandkar A, D’Ambrosio M, et al. Senescence reprogramming by TIMP1 deficiency promotes prostate cancer metastasis. Cancer Cell. 2021; 39(1): 68-82. e69.

[199] Culig Z. Interleukin-6 function and targeting in prostate cancer. Adv Exp Med Biol. 2021; 1290: 1-8.

[200] Fizazi K, De Bono JS, Flechon A, et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer. 2012; 48(1): 85-93.

[201] Culig Z, Pencik J, Merkel O, Kenner L. Breaking a paradigm: iL-6/STAT3 signaling suppresses metastatic prostate cancer upon ARF expression. Mol Cell Oncol. 2016; 3(2): e1090048.

[202] Don-Doncow N, Marginean F, Coleman I, et al. Expression of STAT3 in prostate cancer metastases. Eur Urol. 2017; 71(3): 313-316.

[203] Thulin MH, Määttä J, Linder A, et al. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo. Prostate. 2021; 81(8): 452-462.

[204] Malaquin N, Vancayseele A, Gilbert S, et al. DNA damage-but not enzalutamide-induced senescence in prostate cancer promotes senolytic Bcl-xL inhibitor sensitivity. Cells. 2020; 9(7): 1593.

[205] Roy AL, Sierra F, Howcroft K, et al. A Blueprint for Characterizing Senescence. Cell. 2020; 183(5): 1143-1146.

[206] Battram AM, Bachiller M, Martin-Antonio B. Senescence in the development and response to cancer with immunotherapy: a double-edged sword. Int J Mol Sci. 2020; 21(12): 4346.

[207] Gasek NS, Kuchel GA, Kirkland JL, Xu M. Strategies for targeting senescent cells in human disease. Nat Aging. 2021; 1(10): 870-879.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.